Ang-1 Gene Therapy Inhibits Hypoxia-Inducible Factor-1α (HIF-1α)-Prolyl-4-Hydroxylase-2, Stabilizes HIF-1α Expression, and Normalizes Immature Vasculature in db/db Mice

OBJECTIVE— Diabetic impaired angiogenesis is associated with impairment of hypoxia-inducible factor-1α (HIF-1α) as well as vasculature maturation. We investigated the potential roles and intracellular mechanisms of angiopoietin-1 (Ang-1) gene therapy on myocardial HIF-1α stabilization and vascular maturation in db/db mice. RESEARCH DESIGN AND METHODS— db/db mice were systemically administrated adenovirus Ang-1 (Ad-CMV-Ang-1). Myocardial HIF-1α, vascular endothelial growth factor (VEGF), hemeoxygenase-1 (HO-1), endothelial nitric oxide synthase (eNOS), Akt, and HIF-1α–prolyl-4-hydroxylase-2 (PHD)2 expression were measured. Vasculature maturation, capillary and arteriole densities, and cardiac interstitial fibrosis were analyzed in the border zone of infarcted myocardium. RESULTS— Systemic administration of Ad-CMV-Ang-1 results in overexpression of Ang-1 in db/db mice hearts. Ang-1 gene therapy causes a significant increase in Akt and eNOS expression and HIF-1α stabilization. This is accompanied by a significant upregulation of VEGF and HO-1 expression. Intriguingly, Ang-1 gene therapy also leads to a significant inhibition of PHD2 expression. Smooth muscle recruitment and smooth muscle coverage in the neovessels of the border zone of infarcted myocardium are severely impaired in db/db mice compared with wild-type mice. Ang-1 gene therapy rescues these abnormalities, which leads to a dramatic increase in capillary and arteriole densities and a significant reduction of cardiac hypertrophy and interstitial fibrosis at 14 days after ischemia. Taken together, our data show that Ang-1 increases myocardial vascular maturation and angiogenesis together with suppression of PHD2 and the upregulation of HIF-1α signaling. CONCLUSIONS— Normalization of immature vasculature by Ang-1 gene therapy may represent a novel therapeutic strategy for treatment of the diabetes-associated impairment of myocardial angiogenesis.

[1]  Jian-Xiong Chen,et al.  Disruption of Ang-1/Tie-2 Signaling Contributes to the Impaired Myocardial Vascular Maturation and Angiogenesis in Type II Diabetic Mice , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[2]  Renee Dickie,et al.  The FASEB Journal • Research Communication Integrin binding angiopoietin-1 monomers reduce cardiac hypertrophy , 2022 .

[3]  J. Aschner,et al.  Critical role of angiopoietins/Tie-2 in hyperglycemic exacerbation of myocardial infarction and impaired angiogenesis. , 2008, American journal of physiology. Heart and circulatory physiology.

[4]  G. Semenza,et al.  Hypoxia-Inducible Factor 1 (HIF-1) Pathway , 2007, Science's STKE.

[5]  K. Takeda,et al.  Essential Role for Prolyl Hydroxylase Domain Protein 2 in Oxygen Homeostasis of the Adult Vascular System , 2007, Circulation.

[6]  S. Kihara,et al.  Adiponectin protects against the development of systolic dysfunction following myocardial infarction. , 2007, Journal of molecular and cellular cardiology.

[7]  J. Aschner,et al.  NADPH oxidase modulates myocardial Akt, ERK1/2 activation, and angiogenesis after hypoxia-reoxygenation. , 2007, American journal of physiology. Heart and circulatory physiology.

[8]  J. Fandrey,et al.  Nitric Oxide Modulates Oxygen Sensing by Hypoxia-inducible Factor 1-dependent Induction of Prolyl Hydroxylase 2* , 2007, Journal of Biological Chemistry.

[9]  M. Entman,et al.  The role of platelet-derived growth factor signaling in healing myocardial infarcts. , 2006, Journal of the American College of Cardiology.

[10]  N. Frangogiannis The mechanistic basis of infarct healing. , 2006, Antioxidants & redox signaling.

[11]  B. Meyrick,et al.  Angiopoietin-1-induced angiogenesis is modulated by endothelial NADPH oxidase. , 2006, American journal of physiology. Heart and circulatory physiology.

[12]  G. Koh,et al.  Renoprotective effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  A. Aplin,et al.  Angiopoietin-1 and vascular endothelial growth factor induce expression of inflammatory cytokines before angiogenesis. , 2006, Physiological genomics.

[14]  P. Ratcliffe,et al.  HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation. , 2006, Journal of molecular and cellular cardiology.

[15]  I. Shiojima,et al.  Vascular Endothelial Growth Factor Blockade Promotes the Transition From Compensatory Cardiac Hypertrophy to Failure in Response to Pressure Overload , 2006, Hypertension.

[16]  Tetsuhiro Tanaka,et al.  High glucose blunts vascular endothelial growth factor response to hypoxia via the oxidative stress-regulated hypoxia-inducible factor/hypoxia-responsible element pathway. , 2006, Journal of the American Society of Nephrology : JASN.

[17]  A. Gabrielsen,et al.  Myocardial Gene Expression of Angiogenic Factors in Human Chronic Ischemic Myocardium: Influence of Acute Ischemia/Cardioplegia and Reperfusion , 2006, Microcirculation.

[18]  H. Augustin,et al.  Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation , 2006, Nature Medicine.

[19]  A. Fowler,et al.  Hypoxia Inducible Factor-1 Activation by Prolyl 4-Hydroxylase-2 Gene Silencing Attenuates Myocardial Ischemia Reperfusion Injury , 2005, Circulation research.

[20]  Frank J. Gonzalez,et al.  Loss of ARNT/HIF1β Mediates Altered Gene Expression and Pancreatic-Islet Dysfunction in Human Type 2 Diabetes , 2005, Cell.

[21]  A. Kotanidou,et al.  Angiopoietin-2 Causes Inflammation in Vivo by Promoting Vascular Leakage , 2005, Journal of Pharmacology and Experimental Therapeutics.

[22]  I. Shiojima,et al.  Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. , 2005, The Journal of clinical investigation.

[23]  L. Poellinger,et al.  Hyperglycemia regulates hypoxia-inducible factor-1alpha protein stability and function. , 2004, Diabetes.

[24]  T. Dieterle,et al.  A versatile in vitro assay for investigating angiogenesis of the heart. , 2004, Experimental cell research.

[25]  A. Harris,et al.  Differential Function of the Prolyl Hydroxylases PHD1, PHD2, and PHD3 in the Regulation of Hypoxia-inducible Factor* , 2004, Journal of Biological Chemistry.

[26]  S. Cuzzocrea,et al.  Expression of angiogenic factors during acute coronary syndromes in human type 2 diabetes. , 2004, Diabetes.

[27]  Yi Wei,et al.  Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). , 2004, Genes & development.

[28]  B. Meyrick,et al.  HSP90 and Akt modulate Ang-1-induced angiogenesis via NO in coronary artery endothelium. , 2004, Journal of applied physiology.

[29]  M. Entman,et al.  Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. , 2004, The American journal of pathology.

[30]  G. Semenza,et al.  Nitric Oxide Induces Hypoxia-inducible Factor 1 Activation That Is Dependent on MAPK and Phosphatidylinositol 3-Kinase Signaling* , 2004, Journal of Biological Chemistry.

[31]  F. Coulet,et al.  Identification of Hypoxia-response Element in the Human Endothelial Nitric-oxide Synthase Gene Promoter* , 2003, Journal of Biological Chemistry.

[32]  B. Brüne,et al.  Nitric oxide impairs normoxic degradation of HIF-1alpha by inhibition of prolyl hydroxylases. , 2003, Molecular biology of the cell.

[33]  D. Stewart,et al.  Protective Role of Angiopoietin-1 in Experimental Pulmonary Hypertension , 2003, Circulation research.

[34]  Jiahuai Han,et al.  Requisite Role of p38 MAPK in Mural Cell Recruitment during Angiogenesis in the Rat Aorta Model , 2003, Journal of Vascular Research.

[35]  R. Marfella,et al.  Myocardial infarction in diabetic rats: role of hyperglycaemia on infarct size and early expression of hypoxia-inducible factor 1 , 2002, Diabetologia.

[36]  S. Bursell,et al.  Suppression of diabetic retinopathy with angiopoietin-1. , 2002, The American journal of pathology.

[37]  M. Entman,et al.  Morphological Characteristics of the Microvasculature in Healing Myocardial Infarcts , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[38]  B. Brüne,et al.  Induction of hypoxia-inducible-factor 1 by nitric oxide is mediated via the PI 3K pathway. , 2000, Biochemical and biophysical research communications.

[39]  N. Glazer,et al.  Angiopoietin-1 protects the adult vasculature against plasma leakage , 2000, Nature Medicine.

[40]  D. Mottet,et al.  Hypoxia‐induced activation of HIF‐1: role of HIF‐1α‐Hsp90 interaction , 1999 .

[41]  G. Yancopoulos,et al.  New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF , 1999, Oncogene.

[42]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[43]  Thomas N. Sato,et al.  Increased vascularization in mice overexpressing angiopoietin-1. , 1998, Science.

[44]  Pamela F. Jones,et al.  Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.

[45]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.

[46]  S. Kourembanas,et al.  Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. , 1995, Circulation research.

[47]  Jenny E Gunton,et al.  Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. , 2005, Cell.

[48]  D. Mottet,et al.  Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. , 1999, FEBS letters.